US sends Brazil malaria drug unproven for COVID-19 treatment
The U.S. has sent to Brazil more than 2 million doses of a malaria drug touted by President Donald Trump as potentially protecting against and treating the coronavirus, even though scientific evidence has not backed up those uses.
RELATED: My 'decision to make': Trump defends criticized use of hydroxychloroquine
No large, rigorous scientific studies have found the drug, hydroxychloroquine, safe or effective for preventing or treating COVID-19, and some smaller studies have indicated worse outcomes from those taking the drug.
Brazil, now Latin America’s hardest-hit country, continues to see a surge in virus cases, and last week Trump announced that the U.S. was restricting travel from the country to prevent travelers from spreading the virus in the U.S.
In a joint statement with the Brazilian government on Sunday, the White House said the doses of hydroxychloroquine had been sent to Brazil as a prophylactic for front-line health workers and as a therapeutic for those who may come down with the virus. The White House said it was also delivering 1,000 ventilators to Brazil.
Trump revealed in May that he took a two-week course of the drug to protect against the coronavirus, despite warnings from his own government that it should only be administered for COVID-19 in a hospital or research setting due to potentially fatal side effects.
RELATED: Large study finds malaria drugs touted by Trump linked to greater risk of death in COVID-19 patients
Trump’s announcement that he was taking the drug was criticized by medical experts who warned that his actions could encourage others to take the drug outside of a medical setting.
Trump said he decided to take hydroxychloroquine after two White House staffers tested positive for the disease.